AIMS/HYPOTHESIS: Circulating fibroblast growth factor 21 (FGF21) levels are often elevated in obesity, dyslipidaemia, insulin resistance and type 2 diabetes. This study investigated the relationship of plasma FGF21 levels with cardiovascular events in patients with type 2 diabetes. METHODS:Plasma FGF21 levels were measured by ELISA at baseline in 9,697 individuals with type 2 diabetes participating in theFenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. We assessed the association of FGF21 levels with the incidence of different cardiovascular outcomes over 5 years. The primary outcome was total cardiovascular disease (CVD) events and the secondary outcomes were the four individual components: coronary heart disease events, total stroke, CVD mortality and coronary and carotid revascularisation. The tertiary outcome was hospitalisation for angina pectoris. RESULTS:Higher baseline FGF21 levels were associated with higher risks of all cardiovascular outcome events after adjusting for the study treatment allocation (all p < 0.01). The associations remained significant for total CVD events and for coronary and carotid revascularisation after further adjusting for confounding factors, with the HR (95% CI) being 1.28 (1.10, 1.50) and 1.26 (1.01, 1.56), respectively, for the highest tertile compared with the lowest tertile (overall effect p = 0.002 and 0.007, respectively). The addition of FGF21 levels to a model including established CVD risk factors predicting total CVD events led to a non-significant increase in the C-statistic but there was a significant improvement in integrated discrimination and net reclassification. CONCLUSIONS/ INTERPRETATION:Higher baseline plasma FGF21 levels were associated with higher risk of cardiovascular events in patients with type 2 diabetes. TRIAL REGISTRATION: ISRCTN64783481.
RCT Entities:
AIMS/HYPOTHESIS: Circulating fibroblast growth factor 21 (FGF21) levels are often elevated in obesity, dyslipidaemia, insulin resistance and type 2 diabetes. This study investigated the relationship of plasma FGF21 levels with cardiovascular events in patients with type 2 diabetes. METHODS: Plasma FGF21 levels were measured by ELISA at baseline in 9,697 individuals with type 2 diabetes participating in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. We assessed the association of FGF21 levels with the incidence of different cardiovascular outcomes over 5 years. The primary outcome was total cardiovascular disease (CVD) events and the secondary outcomes were the four individual components: coronary heart disease events, total stroke, CVD mortality and coronary and carotid revascularisation. The tertiary outcome was hospitalisation for angina pectoris. RESULTS: Higher baseline FGF21 levels were associated with higher risks of all cardiovascular outcome events after adjusting for the study treatment allocation (all p < 0.01). The associations remained significant for total CVD events and for coronary and carotid revascularisation after further adjusting for confounding factors, with the HR (95% CI) being 1.28 (1.10, 1.50) and 1.26 (1.01, 1.56), respectively, for the highest tertile compared with the lowest tertile (overall effect p = 0.002 and 0.007, respectively). The addition of FGF21 levels to a model including established CVD risk factors predicting total CVD events led to a non-significant increase in the C-statistic but there was a significant improvement in integrated discrimination and net reclassification. CONCLUSIONS/ INTERPRETATION: Higher baseline plasma FGF21 levels were associated with higher risk of cardiovascular events in patients with type 2 diabetes. TRIAL REGISTRATION: ISRCTN64783481.
Authors: Gregory Gaich; Jenny Y Chien; Haoda Fu; Leonard C Glass; Mark A Deeg; William L Holland; Alexei Kharitonenkov; Thomas Bumol; Holger K Schilske; David E Moller Journal: Cell Metab Date: 2013-09-03 Impact factor: 27.287
Authors: A C Keech; P Mitchell; P A Summanen; J O'Day; T M E Davis; M S Moffitt; M-R Taskinen; R J Simes; D Tse; E Williamson; A Merrifield; L T Laatikainen; M C d'Emden; D C Crimet; R L O'Connell; P G Colman Journal: Lancet Date: 2007-11-07 Impact factor: 79.321
Authors: Marja-Riitta Taskinen; David R Sullivan; Christian Ehnholm; Malcolm Whiting; Diana Zannino; R John Simes; Anthony C Keech; Philip J Barter Journal: Arterioscler Thromb Vasc Biol Date: 2009-03-26 Impact factor: 8.311
Authors: M Lenart-Lipińska; B Matyjaszek-Matuszek; W Gernand; A Nowakowski; J Solski Journal: Diabetes Res Clin Pract Date: 2013-06-12 Impact factor: 5.602
Authors: Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu Journal: Diabetes Date: 2008-02-05 Impact factor: 9.461
Authors: Kwok-Leung Ong; Robyn L McClelland; Matthew A Allison; John Kokkinos; Ben J Wu; Philip J Barter; Kerry-Anne Rye Journal: Atherosclerosis Date: 2018-10-17 Impact factor: 5.162
Authors: Kwok-Leung Ong; Andrzej S Januszewski; Rachel O'Connell; Luke Buizen; Alicia J Jenkins; Aimin Xu; David R Sullivan; Philip J Barter; Russell S Scott; Marja-Riitta Taskinen; Kerry-Anne Rye; Anthony C Keech Journal: Diabetologia Date: 2015-06-09 Impact factor: 10.122
Authors: Tsz Him Hui; Robyn L McClelland; Matthew A Allison; Carlos J Rodriguez; Richard A Kronmal; Susan R Heckbert; Erin D Michos; Philip J Barter; Kerry-Anne Rye; Kwok Leung Ong Journal: Atherosclerosis Date: 2017-12-25 Impact factor: 5.162
Authors: Salah Sommakia; Naredos H Almaw; Sandra H Lee; Dinesh K A Ramadurai; Iosif Taleb; Christos P Kyriakopoulos; Chris J Stubben; Jing Ling; Robert A Campbell; Rami A Alharethi; William T Caine; Sutip Navankasattusas; Guillaume L Hoareau; Anu E Abraham; James C Fang; Craig H Selzman; Stavros G Drakos; Dipayan Chaudhuri Journal: Circ Heart Fail Date: 2021-12-06 Impact factor: 8.790